Vaxcyte, Inc. (NASDAQ:PCVX) Stake Lifted by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 75.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,600 shares of the company's stock after acquiring an additional 41,517 shares during the period. Envestnet Asset Management Inc. owned approximately 0.07% of Vaxcyte worth $3,648,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. National Bank of Canada FI acquired a new stake in Vaxcyte during the fourth quarter valued at approximately $41,000. Parallel Advisors LLC lifted its position in shares of Vaxcyte by 203.6% in the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after acquiring an additional 1,071 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Vaxcyte in the 4th quarter valued at approximately $214,000. XTX Topco Ltd purchased a new stake in shares of Vaxcyte in the 4th quarter valued at approximately $248,000. Finally, Forum Financial Management LP purchased a new stake in shares of Vaxcyte in the 4th quarter valued at approximately $255,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of Vaxcyte in a research report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Bank of America reduced their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. The Goldman Sachs Group reduced their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Finally, Needham & Company LLC restated a "buy" rating and issued a $90.00 price target on shares of Vaxcyte in a research report on Tuesday, April 8th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $136.50.

Vaxcyte Stock Up 1.1%

Shares of PCVX opened at $36.63 on Friday. The company's fifty day moving average is $34.38 and its 200-day moving average is $51.97. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $121.06. The firm has a market cap of $4.73 billion, a price-to-earnings ratio of -9.18 and a beta of 1.19.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the prior year, the business posted ($0.85) EPS. As a group, research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.